Citations

Mayo Clinic

Showing 10 of 108602 citations.

Trends in gender, race, and ethnic diversity among prospective physical medicine and rehabilitation physicians
Dixon, Grant , McGeary, Donald D. , Washington, Mariam, Houle, Tim T., Schappell, Justin B., Smith, Sarah , Silver, Julie , Schappell, Justin , Verduzco-Gutierrez, Monica , Dixon, Grant , Silver, Julie K. , Stampas, Argyrios , Verduzco‐Gutierrez, Monica

PM&R | March 17, 2023 | Volume: 15 | Issue: 11 | Pages: 1445-1456

10.1002/pmrj.12970 | PMID 36930949 Get It

AbstractBackgroundAs the proportion of women and individuals who are underrepresented in medicine slowly rises, disparities persist in numerous arenas and specialties. In physical medicine and rehabilitation (PM&R), there is a continued need to focus on diversity among trainees. This study aims to evaluate diversity among PM&R applicants and residents over the past 6 years.ObjectiveTo describe the demographic trends in PM&R over the last 6 years and compare those findings with trends in other specialties.DesignSurveillance.SettingAnalyses of national databases from self‐reported questionnaires.ParticipantsThe study consists of 126,833 medical school matriculants, 374,185 resident applicants, and 326,134 resident trainees over the last 6 years.Main outcome measuresSelf‐reported demographic data from the Association of American Medical Colleges and the Accreditation Council for Graduate Medical Education were analyzed for medical school matriculants, PM&R applicants, and current residents for the cycles of 2014–2015 to 2019–2020. The data were then comparatively reviewed between PM&R and other medical specialties.ResultsIn the 6 cycles evaluated, women accounted for 36%–39% of PM&R residents, but 47%–48% in non‐PM&R specialties. Women applicants to the PM&R specialty averaged 34.4% over the 6 years analyzed, which was the fourth lowest of the 11 specialties examined. Black or African American and Hispanic, Latino, or of Spanish Origin populations each accounted for only 6% of PM&R residents. PM&R demonstrated a noticeably higher proportion of White (62.1% vs. 60.3%) and an observably lower proportion of Black or African American (6.0% vs. 7.1%) and Hispanic, Latino, or of Spanish Origin (6.3% vs. 7.9%) residents compared with non‐PM&R specialties.ConclusionThere is underrepresentation of women and multiple racial and ethnic minority groups in the field of PM&R from applicants to trainees demonstrating a need to improve recruitment efforts.
Long-Term Performance of an Image-Based Short-Term Risk Model for Breast Cancer
Eriksson, Mikael , Vachon, Celine M. , Conant, Emily F. , Hall, Per , Vachon, Celine M. , Conant, Emily F , Hall, Per N , Eriksson, Mikael , Czene, Kamila

Journal of Clinical Oncology | March 17, 2023 | Volume: 41 | Issue: 14 | Pages: 2536-2545

10.1200/jco.22.01564 | PMID 36930854 Get It

PURPOSE Image-derived artificial intelligence–based short-term risk models for breast cancer have shown high discriminatory performance compared with traditional lifestyle/familial-based risk models. The long-term performance of image-derived risk models has not been investigated. METHODS We performed a case-cohort study of 8,604 randomly selected women within a mammography screening cohort initiated in 2010 in Sweden for women age 40-74 years. Mammograms, age, lifestyle, and familial risk factors were collected at study entry. In all, 2,028 incident breast cancers were identified through register matching in May 2022 (206 incident breast cancers were found in the subcohort). The image-based model extracted mammographic features (density, microcalcifications, masses, and left-right breast asymmetries of these features) and age from study entry mammograms. The Tyrer-Cuzick v8 risk model incorporates self-reported lifestyle and familial risk factors and mammographic density to estimate risk. Absolute risks were estimated, and age-adjusted AUC model performances (aAUCs) were compared across the 10-year period. RESULTS The aAUCs of the image-based risk model ranged from 0.74 (95% CI, 0.70 to 0.78) to 0.65 (95% CI, 0.63 to 0.66) for breast cancers developed 1-10 years after study entry; the corresponding Tyrer-Cuzick aAUCs were 0.62 (95% CI, 0.56 to 0.67) to 0.60 (95% CI, 0.58 to 0.61). For symptomatic cancers, the aAUCs for the image-based model were ≥0.75 during the first 3 years. Women with high and low mammographic density showed similar aAUCs. Throughout the 10-year follow-up, 20% of all women with breast cancers were deemed high-risk at study entry by the image-based risk model compared with 7.1% using the lifestyle familial-based model ( P < .01). CONCLUSION The image-based risk model outperformed the Tyrer-Cuzick v8 model for both short-term and long-term risk assessment and could be used to identify women who may benefit from supplemental screening and risk reduction strategies.
The American Board of Clinical Neuropsychology (ABCN) and American Academy of Clinical Neuropsychology (AACN): Recent milestones and future goals 2014–2023
Bodin, Doug , Beebe, Dean W. , Fuchs, Kathleen , Lucas, John A. , Marcopulos, Bernice A. , Lucas, John, Marcopulos, Bernice

The Clinical Neuropsychologist | March 17, 2023 | Volume: 37 | Issue: 4 | Pages: 784-811

10.1080/13854046.2023.2190538 | PMID 36931232 Get It

Long‐term outcomes in ALG13‐Congenital Disorder of Glycosylation
Shah, Rameen , Johnsen, Christin , Pletcher, Beth A. , Edmondson, Andrew C. , Edmondson, Andrew C , Kozicz, Tamás , Morava, Éva

American Journal of Medical Genetics Part A | March 17, 2023 | Volume: 191 | Issue: 6 | Pages: 1626-1631

10.1002/ajmg.a.63179 | PMID 36930724 Get It

AbstractALG13‐CDG is a rare X‐linked disorder of N‐linked glycosylation. Given the lack of long‐term outcome data in ALG13‐CDG, we collected natural history data and reviewed individuals surviving to young adulthood with confirmed pathogenic variants in ALG13 in our own cohort and in the literature. From the 14 ALG13‐CDG patients enrolled into our Frontiers of Congenital Disorders of Glycosylation Consortium natural history study only two patients were older than 16 years; one of these two females is so far unreported. From the 52 patients described in the medical literature with confirmed pathogenic variants in ALG13 only five patients were older than 16 years (all females), in addition to the new, unreported patient from our natural history study. Two male patients have died due to ALG13‐CDG, and there were no surviving males older than 16 years with a confirmed ALG13‐CDG diagnosis. Our adolescent and young adult cohort of six patients presented with epilepsy, muscular hypotonia, speech, and developmental delay. Intellectual disability was present in all female patients with ALG13‐CDG. Unreported features included ataxia, neuropathy, and severe gastrointestinal symptoms requiring G/J tube placement. In addition, two patients from our natural history study developed unilateral hearing loss. Skeletal abnormalities were found in four patients, including osteopenia and scoliosis. Major health problems included persistent seizures in three patients. Ketogenic diet was efficient for seizures in three out of four patients. Although all patients were mobile, they all had severe communication problems with mostly absent speech and were unable to function without parental support. In summary, long‐term outcome in ALG13‐CDG includes gastrointestinal and skeletal involvement in addition to a chronic, mostly non‐progressive neurologic phenotype.
Clinical presentation, hemorrhage risk, and outcome in patients with familial cavernous malformations: a pragmatic prospective analysis of 75 patients
Alalfi, Mohammed O. , Lanzino, Giuseppe , Flemming, Kelly D.

Journal of Neurosurgery | March 17, 2023 | Volume: 139 | Issue: 4 | Pages: 1018-1024

10.3171/2023.1.jns222434 | PMID 36933254 Get It

OBJECTIVE Newly diagnosed patients with a familial cavernous malformation (FCM) and their families are concerned about their future outlook, which is scarcely discussed in the literature. The authors studied a prospective contemporary cohort of patients with FCMs to assess demographics, mode of presentation, prospective risk of hemorrhage and seizures, need for surgery, and functional outcome over an extended interval. METHODS A prospectively maintained database beginning January 1, 2015, of patients diagnosed with a cavernous malformation (CM) was queried. Data on demographics, radiological imaging, and symptoms at first diagnosis were collected in adult patients who gave their consent to prospective contact. Follow-up was done using questionnaires, in-person visits, and medical record review to assess for prospective symptomatic hemorrhage (i.e., the first hemorrhage after enrollment in the database), seizure, functional outcome measured by the modified Rankin Scale (mRS), and treatment. The prospective hemorrhage rate was calculated by the number of prospective hemorrhages divided by patient-years of follow-up censored at last follow-up, first prospective hemorrhage, or death. A Kaplan-Meier curve of survival free of hemorrhage was obtained comparing patients with versus without hemorrhage at the time of presentation and compared with a log-rank test for p < 0.05. RESULTS A total of 75 patients with FCM were included, of whom 60% were female. The mean age at diagnosis was 41 ± 16 years. Most symptomatic or large lesions were located supratentorially. At first diagnosis, 27 patients had no symptoms, and the remaining were symptomatic. Over an average of 9.9 years, the rate of prospective hemorrhage was 4.0% per patient-year, and the rate of new seizure was 1.2% per patient-year, with 64% and 32% of patients experiencing at least one symptomatic hemorrhage and at least one seizure, respectively. Thirty-eight percent of the patients underwent at least 1 surgery and 5.3% underwent stereotactic radiosurgery. At the last follow-up, 83.0% of patients remained independent with an mRS score ≤ 2. CONCLUSIONS The authors’ findings provide clinically useful information on hemorrhage rate, seizure rate, the likelihood of surgery, and functional outcome. These findings can be helpful to practicing physicians when counseling patients with FCM and their families, who are often apprehensive about their future and well-being.
Intraoperative diagnosis of facial schwannomas: a multicenter summation of clinical experience, preoperative avoidance, and intraoperative management protocol
Plitt, Aaron , Snyder, Lauren Rose, Hammerbeck-Ward, Charlotte , Neff, Brian A., Driscoll, Colin L. W., Carlson, Matthew L. , Lane, John I. , Lloyd, Simon , Freeman, Simon , Laitt, Roger, Abdulla, Sarah , Siripurapu, Rekha, Potter, Gillian , Link, Michael J., Rutherford, Scott , Plitt, Aaron R, Driscoll, Colin L., Lewis, Daniel , Hannan, Cathal John , Richardson, George E. , King, Andrew Thomas , Pathmanaban, Omar Nathan , Gompel, Jamie J. Van , Link, Michael J.

Journal of Neurosurgery | March 17, 2023 | Volume: 139 | Issue: 4 | Pages: 972-983

10.3171/2023.2.jns222368 | PMID 36933255 Get It

OBJECTIVE Preoperative differentiation of facial nerve schwannoma (FNS) from vestibular schwannoma (VS) can be challenging, and failure to differentiate between these two pathologies can result in potentially avoidable facial nerve injury. This study presents the combined experience of two high-volume centers in the management of intraoperatively diagnosed FNSs. The authors highlight clinical and imaging features that can distinguish FNS from VS and provide an algorithm to help manage intraoperatively diagnosed FNS. METHODS Operative records of 1484 presumed sporadic VS resections between January 2012 and December 2021 were reviewed, and patients with intraoperatively diagnosed FNSs were identified. Clinical data and preoperative imaging were retrospectively reviewed for features suggestive of FNS, and factors associated with good postoperative facial nerve function (House-Brackmann [HB] grade ≤ 2) were identified. A preoperative imaging protocol for suspected VS and recommendations for surgical decision-making following an intraoperative FNS diagnosis were created. RESULTS Nineteen patients (1.3%) with FNSs were identified. All patients had normal facial motor function preoperatively. In 12 patients (63%), preoperative imaging demonstrated no features suggestive of FNS, with the remainder showing subtle enhancement of the geniculate/labyrinthine facial segment, widening/erosion of the fallopian canal, or multiple tumor nodules in retrospect. Eleven (57.9%) of the 19 patients underwent a retrosigmoid craniotomy, and in the remaining patients, a translabyrinthine (n = 6) or transotic (n = 2) approach was used. Following FNS diagnosis, 6 (32%) of the tumors underwent gross-total resection (GTR) and cable nerve grafting, 6 (32%) underwent subtotal resection (STR) and bony decompression of the meatal facial nerve segment, and 7 (36%) underwent bony decompression only. All patients undergoing subtotal debulking or bony decompression exhibited normal postoperative facial function (HB grade I). At the last clinical follow-up, patients who underwent GTR with a facial nerve graft had HB grade III (3 of 6 patients) or IV facial function. Tumor recurrence/regrowth occurred in 3 patients (16%), all of whom had been treated with either bony decompression or STR. CONCLUSIONS Intraoperative diagnosis of an FNS during a presumed VS resection is rare, but its incidence can be reduced further by maintaining a high index of suspicion and undertaking further imaging in patients with atypical clinical or imaging features. If an intraoperative diagnosis does occur, conservative surgical management with bony decompression of the facial nerve only is recommended, unless there is significant mass effect on surrounding structures.
Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy
Marar, Rosalyn, Abbasi, Muhannad , Prathivadhi-Bhayankaram, Sruti , Daryanani, Andres , Villarraga, Hector R. , Anavekar, Nandan S., Bhatt, Vijaya Raj , Abbasi, Muhannad Aboud , Villarraga, Hector R , Paludo, Jonas , Bhatt, Vijaya Raj , Paludo, Jonas

JCO Oncology Practice | March 17, 2023 | Volume: 19 | Issue: 6 | Pages: 331-342

10.1200/op.22.00713 | PMID 36930845 Get It

The field of malignant hematology is transforming with novel immunotherapeutic approaches. Unfortunately, quality of life, treatment efficacy, and life expectancy are negatively affected by cardiotoxic side effects of treatment. To date, the exact mechanism and incidence of cardiotoxicity associated with these therapies is unclear. These events are believed to be triggered or occur concurrently with cytokine release syndrome. Furthermore, there are no formal guidelines to provide evaluation, treatment, and surveillance. We aim to synthesize available literature with updates on the cardiotoxic effects of novel therapies used in malignant hematologic disorders, with a focus on chimeric antigen receptor T-cell therapy and bispecific T-cell engager therapy, along with a proposed algorithm that may guide pretreatment evaluation, monitoring during treatment, and post-treatment surveillance.
Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions
Lindström, Sara , Wang, Lu , Feng, Helian , Huo, Sijia , Harrison, Tabitha A. , Turman, Constance , Chen, Hongjie , Bammler, Theo K. , Gallinger, Steve, Gruber, Stephen B. , Moreno, Vı́ctor , Offit, Kenneth , O’Mara, Tracy A. , Tomlinson, Ian, Gharahkhani, Puya , MacGregor, Stuart , Schumacher, Johannes , Bondy, Melissa L. , Houlston, Richard S. , Jenkins, Robert B. , Melin, Beatrice , Wrensch, Margaret , Brennan, Paul , Johansson, Mattias , McKay, James , Aldrich, Melinda C. , Landi, Maria Teresa , Bishop, D. Timothy , Iles, Mark M. , Law, Matthew H. , Wolpin, Brian M. , Petersen, Gloria M. , Purdue, Mark P. , Scélo, Ghislaine , Kar, Siddhartha , Hung, Rayjean J, Kraft, Peter , Lissowska, Jolanta , Simard, Jacques , Dörk, Thilo , John, Esther M. , Carracedo, Ángel , Huang, Wen‐Yi , Vodička, Pavel , Taylor, Jack A. , Lessel, Davor , Kurian, Allison W. , Hung, Rayjean J. , Kundaje, Anshul , Zhong, Jun , Turman, Constance , Chen, Hongjie , Gruber, Stephen B , Marchand, Loïc Le , Moreno, Victor , Offit, Kenneth , Gharahkhani, Puya , MacGregor, Stuart , Schumacher, Johannes , Houlston, Richard S , Brennan, Paul , Johansson, Mattias , Iles, Mark M , Law, Matthew H , Amundadottir, Laufey , Klein, Alison P , Petersen, Gloria, Chanock, Stephen Jacob , Kar, Siddhartha , Kraft, Peter , Dörk, Thilo , Lissowska, Jolanta , John, Esther M , Hung, Rayjean J , Harrison, Tabitha A , O'Mara, Tracy A , Lessel, Davor , Bishop, D Timothy , Huang, Wen-Yi , Taylor, Jack A , Simard, Jacques , Kurian, Allison W , Kundaje, Anshul , Vodicka, Pavel , Zhong, Jun , Majumdar, Arunabha , MacDonald, James W. , Mancuso, Nicholas , Gunter, Marc J. , Marchand, Loı̈c Le , Vivo, Immaculata De , Spurdle, Amanda B. , Fitzgerald, Rebecca C. , Gockel, Ines , Jankowski, Janusz , Barnholtz‐Sloan, Jill S. , Christiani, David C. , Amos, Christopher I. , Tardón, Adonina , Démenais, Florence , Goldstein, Alisa M. , Kanetsky, Peter A. , Ámundadóttir, Laufey T. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Risch, Harvey A. , Pharoah, Paul D.P. , Paşaniuc, Bogdan

JNCI: Journal of the National Cancer Institute | March 17, 2023 | Volume: 115 | Issue: 6 | Pages: 712-732

10.1093/jnci/djad043 | PMID 36929942 Get It

Abstract Background The shared inherited genetic contribution to risk of different cancers is not fully known. In this study, we leverage results from 12 cancer genome-wide association studies (GWAS) to quantify pairwise genome-wide genetic correlations across cancers and identify novel cancer susceptibility loci. Methods We collected GWAS summary statistics for 12 solid cancers based on 376 759 participants with cancer and 532 864 participants without cancer of European ancestry. The included cancer types were breast, colorectal, endometrial, esophageal, glioma, head and neck, lung, melanoma, ovarian, pancreatic, prostate, and renal cancers. We conducted cross-cancer GWAS and transcriptome-wide association studies to discover novel cancer susceptibility loci. Finally, we assessed the extent of variant-specific pleiotropy among cancers at known and newly identified cancer susceptibility loci. Results We observed widespread but modest genome-wide genetic correlations across cancers. In cross-cancer GWAS and transcriptome-wide association studies, we identified 15 novel cancer susceptibility loci. Additionally, we identified multiple variants at 77 distinct loci with strong evidence of being associated with at least 2 cancer types by testing for pleiotropy at known cancer susceptibility loci. Conclusions Overall, these results suggest that some genetic risk variants are shared among cancers, though much of cancer heritability is cancer-specific and thus tissue-specific. The increase in statistical power associated with larger sample sizes in cross-disease analysis allows for the identification of novel susceptibility regions. Future studies incorporating data on multiple cancer types are likely to identify additional regions associated with the risk of multiple cancer types.
Adverse events following COVID‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia
Yasmin, Farah , Najeeb, Hala , Naeem, Unaiza , Moeed, Abdul , Atif, Abdul Raafe , Asghar, Muhammad Sohaib , Nimri, Nayef , Saleem, Maryam , Krittanawong, Chayakrit , Eljack, Mohammed Mahmmoud Fadelallah , Tahir, Muhammad Junaid, Waqar, Fahad , Mahmmoud Fadelallah Eljack, Mohammed , Asghar, Muhammad S , Bandyopadhyay, Dhrubajyoti , Krittanawong, Chayakrit

Immunity, Inflammation and Disease | March 17, 2023 | Volume: 11 | Issue: 3 | Pages: No page available

10.1002/iid3.807 | PMID 36988252 Get It

AbstractBackground and ObjectivesSince publishing successful clinical trial results of mRNA coronavirus disease 2019 (COVID‐19) vaccines in December 2020, multiple reports have arisen about cardiovascular complications following the mRNA vaccination. This study provides an in‐depth account of various cardiovascular adverse events reported after the mRNA vaccines' first or second dose including pericarditis/myopericarditis, myocarditis, hypotension, hypertension, arrhythmia, cardiogenic shock, stroke, myocardial infarction/STEMI, intracranial hemorrhage, thrombosis (deep vein thrombosis, cerebral venous thrombosis, arterial or venous thrombotic events, portal vein thrombosis, coronary thrombosis, microvascular small bowel thrombosis), and pulmonary embolism.MethodsA systematic review of original studies reporting confirmed cardiovascular manifestations post‐mRNA COVID‐19 vaccination was performed. Following the PRISMA guidelines, electronic databases (PubMed, PMC NCBI, and Cochrane Library) were searched until January 2022. Baseline characteristics of patients and disease outcomes were extracted from relevant studies.ResultsA total of 81 articles analyzed confirmed cardiovascular complications post‐COVID‐19 mRNA vaccines in 17,636 individuals and reported 284 deaths with any mRNA vaccine. Of 17,636 cardiovascular events with any mRNA vaccine, 17,192 were observed with the BNT162b2 (Pfizer−BioNTech) vaccine, 444 events with mRNA‐1273 (Moderna). Thrombosis was frequently reported with any mRNA vaccine (n = 13,936), followed by stroke (n = 758), myocarditis (n = 511), myocardial infarction (n = 377), pulmonary embolism (n = 301), and arrhythmia (n = 254). Stratifying the results by vaccine type showed that thrombosis (80.8%) was common in the BNT162b2 cohort, while stroke (39.9%) was common with mRNA‐1273 for any dose. The time between the vaccination dosage and the first symptom onset averaged 5.6 and 4.8 days with the mRNA‐1273 vaccine and BNT162b2, respectively. The mRNA‐1273 cohort reported 56 deaths compared to the 228 with BNT162b2, while the rest were discharged or transferred to the ICU.ConclusionAvailable literature includes more studies with the BNT162b2 vaccine than mRNA‐1273. Future studies must report mortality and adverse cardiovascular events by vaccine types.
Is baclofen the least worst option for spasticity management in children?
Brandenburg, Joline E.

Journal of Pediatric Rehabilitation Medicine | March 17, 2023 | Volume: 16 | Issue: 1 | Pages: 11-17

10.3233/prm-230001 | PMID 36938744 Get It

Baclofen is often considered a first-line treatment option for spasticity management in children. However, adverse effects, administration, and dosing can be barriers to effectiveness. In my practice, other medications for spasticity management are often used prior to initiating baclofen. In this article, baclofen use for spasticity management in children is briefly reviewed along with discussion of approaches using other medications as first-line treatment options. I will present a rationale for medication selection for spasticity management and discuss the approaches I take in medication selection that incorporate spasticity severity, patient goals, and medication side effect profiles.